Tambo Ernest, Khater Emad I M, Chen Jun-Hu, Bergquist Robert, Zhou Xiao-Nong
Department of Biochemistry and Pharmaceutical Sciences, Higher Institute of Health Sciences, Université des Montagnes, Bangangté, Cameroon.
Sydney Brenner Institute for Molecular Biosciences, University of the Witwatersrand, Johannesburg, South Africa.
Infect Dis Poverty. 2015 Dec 28;4:58. doi: 10.1186/s40249-015-0091-8.
The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to inflict a disproportionate global public health burden with associated consequences, thereby contributing to the vicious cycle of poverty and inequity. However, the effectiveness and large-scale coverage of artemisinin combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives. The paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the Nobel Prize in Physiology or Medicine in 2015. However, the story would not be complete without mentioning praziquantel. The huge contribution of this drug in modernizing the control of schistosomiasis and also some intestinal helminth infections had already shifted the focus from control to potential elimination of this disease. Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious diseases that humans have lived with since time immemorial. These drugs all have broad-spectrum effects, yet they are very safe and can even be packaged together in various combinations. The strong effect on so many of the great infectious scourges in the developing countries has not only had a remarkable influence on many endemic diseases, but also contributed to improving the cost structure of healthcare. Significant benefits include improved quality of preventive and curative medicine, promotion of community-based interventions, universal health coverage and the fostering of global partnerships. The laudable progress and benefits achieved are indispensable in championing, strengthening and moving forward elimination of the IDoPs. However, there is an urgent need for further innovative, contextual and integrated approaches along with the advent of the Sustainable Development Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.
千年发展目标(MDGs)从一开始就给发展中国家被忽视的弱势群体带来了显著转变,但贫困相关传染病(IDoPs)继续给全球公共卫生造成不成比例的负担,并带来相关后果,从而加剧了贫困与不平等的恶性循环。然而,青蒿素联合疗法(ACT)的有效性和大规模覆盖彻底变革了疟疾治疗,正如淋巴丝虫病(LF)和盘尾丝虫病的防治受益于基于阿维菌素的衍生物的广谱效应一样。这两种药物带来的治疗方法范式转变及其对困扰低收入和中等收入流行国家(LIMCs)的寄生虫病社区干预措施的影响,促成了2015年的诺贝尔生理学或医学奖。然而,不提吡喹酮的话,这个故事就不完整。这种药物在使血吸虫病以及一些肠道蠕虫感染的防治现代化方面做出的巨大贡献,已经将重点从疾病控制转向了该病的潜在消除。总之,这些新药为人类提供了强大的新工具,以减轻人类自古以来就面临的传染病负担。这些药物都具有广谱效应,但非常安全,甚至可以以各种组合形式包装在一起。它们对发展中国家诸多重大传染性灾难的强效作用,不仅对许多地方病产生了显著影响,还有助于改善医疗保健的成本结构。显著的益处包括提高预防和治疗药物的质量、促进基于社区的干预措施、全民健康覆盖以及促进全球伙伴关系。所取得的值得称赞的进展和益处对于支持、加强和推进消除贫困相关传染病至关重要。然而,随着可持续发展目标(SDGs)的出现,迫切需要进一步创新、因地制宜和综合的方法,以取代千年发展目标,确保所有人的全球卫生安全、福祉和经济繁荣。